In February 2026, Labcorp announced nationwide availability of the Elecsys pTau-181 blood test, the first FDA-cleared primary-care tool to aid in ruling out Alzheimer’s disease by identifying ...

Labcorp is now offering Roche Diagnostics' recently FDA-cleared Alzheimer’s disease blood test to help primary care doctors ...

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the nationwide availability of the Elecsys® pTau-181 test, the first and only blood test ...

LH heads into its Q4 earnings report with rising revenue and EPS expectations, driven by Diagnostics momentum, acquisitions ...

FDA clears 1st blood test for Alzheimer’s to help primary care clinicians assess cognitive decline without brain scans or lumbar punctures.

The availability of a four-in-one respiratory virus diagnostic for home use may be a boon to consumers, but some clinicians say it should not be used as a substitute for a physician’s guidance.

Quest Diagnostics on Tuesday forecast 2026 profit and revenue above Wall Street estimates after beating expectations for fourth-quarter results on strong demand for its diagnostic tests.

@hopkinskimmel researchers develop novel liquid biopsy approach to identifying early-stage cancers. › ...

The company inked deals with DoorDash, EverlyWell, Quest, and Labcorp to sell the test for $149—comparable to the cost of STI ...

Q4 earnings season is here, and BSX, ALGN, STE and TECH are set to report amid slowing sector profits but steady revenue ...